[1] DESANTIS CE, MA J, GODING SAUER A, et al.Breast cancer statistics, 2017, racial disparity in mortality by state[J].CA Cancer J Clin, 2017, 67(6):439. doi: 10.3322/caac.21412
[2] SEGAL RL, MILLER KD, JEMAL A.Cancer statistics, 2018[J].CA Cancer J Clin, 2018, 68(1):7. doi: 10.3322/caac.21442
[3] CHOONEVELD EV, WILDIERS H, VERGOTE I, et al.Dysregulationof microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management[J].Breast Cancer Res, 2015, 17(1):21. doi: 10.1186/s13058-015-0526-y
[4] WAHBA HA, AND EL-HADAAD HA.Current approaches in treatment of triple-negative breast cancer[J].Cancer Biol Med, 2015(12):106.
[5] CAO SQ, ZHANG KY, YAN X, et al.Preparation and evaluation of paclitaxel and Brucea javanica oil corematched nanoemulsions to treat cancer in vitro and in vivo[J].Chin Herb Med, 2018, 10(3):310. doi: 10.1016/j.chmed.2018.06.001
[6] YANG Q, HUANG J, WU Q, et al.Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells[J].Br J Cancer, 2014, 110(8):1958. doi: 10.1038/bjc.2014.136
[7] FANG X, YOUSAF M, HUANG Q, et al.Dual effect of PEG-PE micelle over the oligomerization and fibrillation of human islet amyloid polypeptide[J].Sci Rep, 2018, 8(1):4463. doi: 10.1038/s41598-018-22820-w
[8] KOHAY H, SARISOZEN C, SAWANT R, et al.PEG-PE/claycomposite carriers for doxorubicin:Effect of compositestructure on release, cell interaction and cytotoxicity[J].Acta Biomater, 2017, 55(24):443.
[9] SARISOZEN C, VURAL I, LEVCHENKO T, et al.PEG-PE-based micelles co-loaded with taxol and cyclosporine A or loaded with taxol and targeted by anticancer antibody overcome drug resistance in cancer cells[J].Drug Deliv, 2012, 19(4):169. doi: 10.3109/10717544.2012.674163
[10] ZHANG Z, TAN S, FENG SS.Vitamin E TPGS as a molecular biomaterial for drug delivery[J].Biomaterials, 2012, 33(19):4889. doi: 10.1016/j.biomaterials.2012.03.046
[11] HUANG L, CHEN H, ZHENG Y, et al.Nanoformulation of d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy[J].Integrative Biology, 2011, 3(10):993. doi: 10.1039/c1ib00026h
[12] KUTTY RV, CHIA SL, SETYAWATI MI, et al.In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer[J].Biomaterials, 2015, 63:58. doi: 10.1016/j.biomaterials.2015.06.005
[13] YANG Q, HUANG J, WU Q, et al.Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells[J].Br J Cancer, 2014, 110(8):1958. doi: 10.1038/bjc.2014.136
[14] HARVEY V, MOURIDSEN H, SEMIGLAZOV V, et al.Phase Ⅲ trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer[J].J Clin Oncol, 2006, 24(31):4963. doi: 10.1200/JCO.2005.05.0294
[15] JOERGER M, KRAFF S, HUITEMA AD, et al.Evaluation of a pharmacology driven dosing algorithm of 3 weekly paclitaxel using therapeutic drug monitoring[J].Clin Pharmacokinet, 2012, 51(9):607. doi: 10.1007/BF03261934